Curia is a global CDMO with 20 facilities and over 30 years of experience successfully guiding clients through the complexities of drug discovery, development, and manufacturing. We offer services across Small Molecule, Generic APIs, and Biologics, including clinical and commercial drug substance and drug product. Curia specializes in including highly potent, sterile API, controlled substances, and generics.

Company (Headquarters):

United States

Types of Drugs Manufactured:

Small Molecule; Biologics

CDMO Services:

Drug Substance Manufacturing (API);Drug Product/FDF;Research & Development;Packaging(Commercial);Regulatory Services;Analytical Development;Process & Forumulation Development

CDMO Number of Facilities:

20

High Potent Products capabilities:

OEB 3 Medium Potency;OEB 4-5 Highly Potent APIs (HPAPIs);OEB >5 Ultra high potency

Facilities Location:

Europe, North America, South Asia

Regulatory Approvals for facilities:

USA - FDA;Europe - EMA or constituent countries;UK - MHRA;GMP;ISO 9001;Canada - Health Canada;Japan - MHLW;Australia - TGA;South Korea - MFDS;India - CDSCO;ISO 14001;ISO 14644-1;ISO 14698

Manufacturing Technologies:

Cartridges;Lyophilized amps/vials;Oral Liquids;Pre-Filled Syringes (PFS);Sterile Vials

Current Capacity:

Curia currently has capacity in the U.S., Europe, and India for both clinical and commercial programs.